Case report and literature review: efficacy of afatinib in a rare EGFR p.G719A/p.H773L compound-mutant NSCLC with over 54 months of progression-free survival
Compound EGFR mutations involving an exon 18 sensitizing variant and an exon 20 non-insertion point mutations pose a therapeutic dilemma: the former predicts TKI sensitivity, while the latter is frequently annotated as potentially resistant based solely on genomic location, given the absence of direct functional evidence. Here we describe a 66-year-old female never-smoker with advanced lung adenocarcinoma harboring an EGFR p.G719A (exon 18) and p.H773L (exon 20) compound mutation. Despite the unfavorable annotation of H773L, the patient was treated with first-line afatinib 40 mg daily (with subsequent dose reduction to 30 mg for toxicity management). Disease control was maintained through sequential adjustments, including consolidative radiotherapy for oligoprogression after a brief afatinib treatment interruption. Remarkably, the patient achieved a progression-free survival exceeding 54 months. This duration exceeds the typical 13–15 months median PFS reported for pure G719X mutations and represents an exceptional outcome for this specific genotype. These data provide the first clinical evidence that the G719A/H773L compound mutation retains high sensitivity to afatinib, challenging the assumption that all exon 20 non-insertion variants confer TKI resistance. Lacking definitive functional data, our findings support prioritizing the established sensitivity of the dominant driver mutation over theoretical concerns about coexisting variants. This approach offers practical guidance for managing ultra-rare EGFR genotypes.
Authors
- Xin Xun
- Bin Su (ORCID: https://orcid.org/0000-0001-5140-0440)
- Yunfei Ye (ORCID: https://orcid.org/0000-0002-4561-2049)
- Ziran Gao
- Meijin Huang
- Xunzhi Zhu
- Qingxia Yang
- Jun Zhu
- Hong Chen
- Yi Li
Institutions
- Chinese People's Liberation Army (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-11-17
- DOI
- https://doi.org/10.3389/fphar.2026.1952109
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Yunnan Provincial Science and Technology Department